ArticleThe Journal of experimental medicine2022
CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure.
Article in The Journal of experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Sex-Specific Blood Pressure and Brain Microvascular Traits in a Model of Low-Renin Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Sex-specific prediction models for aortic aneurysm integrating traditional clinical risk factors and proteomic profiles: a large-scale prospective study from the UK Biobank.Biology of sex differences · 2026Article
- CC Chemokines in Myocardial Fibrosis: Regulatory Networks of CCL17 and Emerging Therapeutic Implications.International journal of molecular sciences · 2026Review
- Nucleosome stability safeguards cell identity, stress resilience and healthy aging.Research square · 2025Article
- Nucleosome stability safeguards cell identity, stress resilience and healthy aging.bioRxiv : the preprint server for biology · 2025Article
- Pleiotropic role of CCR9/CCL25 signaling in adriamycin-induced cardiomyopathy.Journal of advanced research · 2025Article
- CCL17 Influences Borrelia burgdorferi Infection in the Heart.The Journal of infectious diseases · 2025Article
- Article
- The impact of cellular senescence on aging skeletal muscle.Frontiers in cell and developmental biology · 2025Review
- CXCL13-neutralizing Antibody Alleviate Chronic Skeletal Muscle Degeneration in a Mouse Model.Current molecular medicine · 2025Article
- lncRNA Gm20257 alleviates pathological cardiac hypertrophy by modulating the PGC-1α-mitochondrial complex IV axis.Frontiers of medicine · 2024Article
- MiR-203 improves cardiac dysfunction by targeting PARP1-NADAging cell · 2024Article
- Human amnion epithelial cell therapy reduces hypertension-induced vascular stiffening and cognitive impairment.Scientific reports · 2024Article
- Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease.Journal of the American College of Cardiology · 2023Article
- Discovery of age-related early-stage glycated proteins based on deep quantitative serum glycated proteome analysis.Acta biochimica et biophysica Sinica · 2023Article
- A biomarker framework for cardiac aging: the Aging Biomarker Consortium consensus statement.Life medicine · 2023Article
- Sirtuin 2 deficiency aggravates ageing-induced vascular remodelling in humans and mice.European heart journal · 2023Article
- The application of Aptamer in biomarker discovery.Biomarker research · 2023Review
- The Role of the Piezo1 Mechanosensitive Channel in Heart Failure.Current issues in molecular biology · 2023Review
- Biomarkers of aging.Science China. Life sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Circulating proteomic signatures of age are closely associated with aging and age-related diseases; however, the utility of changes in secreted proteins in identifying therapeutic targets for diseases remains unclear. Serum proteomic profiling of an age-stratified healthy population and further community-based cohort together with heart failure patients study demonstrated that circulating C-C motif chemokine ligand 17 (CCL17) level increased with age and correlated with cardiac dysfunction. Subsequent animal experiments further revealed that Ccll7-KO significantly repressed aging and angiotensin II (Ang II)-induced cardiac hypertrophy and fibrosis, accompanied by the plasticity and differentiation of T cell subsets. Furthermore, the therapeutic administration of an anti-CCL17 neutralizing antibody inhibited Ang II-induced pathological cardiac remodeling. Our findings reveal that chemokine CCL17 is identifiable as a novel therapeutic target in age-related and Ang II-induced pathological cardiac hypertrophy and heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.